Cargando…

Glucagon signaling in the heart: Activation or inhibition?()

Detalles Bibliográficos
Autor principal:	Pocai, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314537/ https://www.ncbi.nlm.nih.gov/pubmed/25685695 http://dx.doi.org/10.1016/j.molmet.2014.12.004

Ejemplares similares

Modulation of Glucagon Signaling: A Metabolic Approach for Heart Failure?
por: Pocai, Alessandro
Publicado: (2019)

GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action
por: Lee, Seunghun P., et al.
Publicado: (2021)

Does glucagon have a positive inotropic effect in the human heart?
por: Hernández-Cascales, Jesus
Publicado: (2018)

A Variation on the Theme: SGLT2 Inhibition and Glucagon Secretion in Human Islets
por: Hodson, David J., et al.
Publicado: (2020)

Regulating Glucagon Secretion: Somatostatin in the Spotlight
por: Rutter, Guy A.
Publicado: (2009)

Glucagon as a Critical Factor in the Pathology of Diabetes
por: Edgerton, Dale S., et al.
Publicado: (2011)

Ketosis-Prone Atypical Diabetes: Glucagon Is There, Too
por: Lefèbvre, Pierre
Publicado: (2013)

Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control
por: Jia, Guanghong, et al.
Publicado: (2016)

Role of Fibroblast Growth Factor 21 in Biology of Glucagon
por: Berglund, Eric D., et al.
Publicado: (2013)

The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
por: Kalra, Sanjay, et al.
Publicado: (2016)

Is ghrelin a glucagon‐like peptide‐1 secretagogue?
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists
por: Pearson, Mackenzie J., et al.
Publicado: (2016)

Clinical relevance of dual agonist of glucagon and glucagon‐like peptide‐1 receptors to achieve functional restoration of first‐ and second‐phase insulin secretion
por: Kimura, Tomohiko, et al.
Publicado: (2022)

The Welcome Resurgence of the α-Cell: A Pro Glucagon Commentary
por: Robertson, R. Paul
Publicado: (2010)

Glucagon Peptide Family and Adipose Tissue: Not that Intimate, just Acquaintances
por: Perez-Tilve, Diego
Publicado: (2020)

Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
por: Araki, Eiichi, et al.
Publicado: (2022)

Glucose Control of Glucagon Secretion: There Is More to It Than K(ATP) Channels
por: Gylfe, Erik
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Regulation of glucagon‐like peptide‐1 sensitivity by gut microbiota dysbiosis
por: Yamane, Shunsuke, et al.
Publicado: (2017)

Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes
por: Cho, Young Min
Publicado: (2022)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Taking Aim at Islet Hormones With GLP-1: Is Insulin or Glucagon the Better Target?
por: D'Alessio, David A.
Publicado: (2010)

Novel Insights Into the Regulation of Postprandial Lipemia by Glucagon-Like Peptides: Significance for Diabetes
por: Watts, Gerald F., et al.
Publicado: (2013)

Glucagon-Like Peptide 1 in the Brain: Where Is It Coming From, Where Is It Going?
por: Daniels, Derek, et al.
Publicado: (2019)

Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021)

The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin
por: Kosinski, Jennifer R., et al.
Publicado: (2012)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice
por: More, Vijay R., et al.
Publicado: (2017)

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?
por: Butler, P. C., et al.
Publicado: (2009)

Puzzling About Partial Glucagon Responses to Hypoglycemia in Intrahepatic Islet Recipients: Missing Pieces
por: Robertson, R. Paul
Publicado: (2015)

Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach
por: Kalra, Sanjay
Publicado: (2014)

Postprandial Insulin Secretion After Gastric Bypass Surgery: The Role of Glucagon-Like Peptide 1
por: Holst, Jens Juul
Publicado: (2011)

The gut-brain axis in the critically ill: Is glucagon-like peptide-1 protective in neurocritical care?
por: Plummer, Mark P, et al.
Publicado: (2013)

Glucagon regulates lipolysis and fatty acid oxidation through inositol triphosphate receptor 1 in the liver
por: Hayashi, Yoshitaka
Publicado: (2020)

Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
por: Kreiner, Frederik Flindt, et al.
Publicado: (2023)

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
por: Zhou, Xiaoyan, et al.
Publicado: (2015)

The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill
por: Deane, Adam M, et al.
Publicado: (2010)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
por: Watada, Hirotaka
Publicado: (2019)

Effects of glucagon‐like peptide‐1 receptor agonists on kidney function and safety in type 2 diabetes patients
por: Kim, Min Kyung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ebmo1lr4do3p94qo1ro43ijmrg